| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/03/2009 | US7498298 Monomethylvaline compounds capable of conjugation to ligands |
| 03/03/2009 | US7498178 Preparing a diamond particle with functional amino group and water by explosion using a detonating agent;oxidation with nitric acid to obtain a suspension liquid including an aggregation of the diamond particle; adding base to neutralize and generate gas; |
| 03/03/2009 | US7498162 A gene expressed polypeptide is used in food, for treating food allergy |
| 03/03/2009 | US7498153 Chimeric immunogens |
| 03/03/2009 | US7498147 Modulating the activity of one or more elements in the complement/lipid pathway |
| 03/03/2009 | US7498143 Identification of Actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 03/03/2009 | US7498142 Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| 03/03/2009 | US7498138 Multimerization of HIV-1 Vif protein as a therapeutic target |
| 03/03/2009 | US7498130 Method of reducing viral load |
| 03/03/2009 | US7498129 Measuring changes in level of antigen recognizable by a monoclonal antibody or antigen binding fragment; monoclonal antibody is produced by hybridoma cell line; decreased level indicates a reduced tumor; diagnosis, cell purification |
| 03/03/2009 | US7498046 Composition for inducing immune response comprising inverted microsomes |
| 03/03/2009 | US7498038 Chitin microparticles and their medical uses |
| 03/03/2009 | US7498037 Expression vector comprising nucleotide sequences coding malarial proteins for use as tool in generating vaccines against plasmodial infection; immunotherapy; antimalarial agents |
| 03/03/2009 | US7498036 Optimized expression of HPV 58 L1 in yeast |
| 03/03/2009 | US7498035 conjugates of methoxylpolyethylene glycol-glutamic acid oligopeptide and drug such as antitumor agents, having low toxicity, improved solubility, sustain and/or control release profiles |
| 03/03/2009 | US7498034 Imaging, diagnosis and treatment of disease |
| 03/03/2009 | US7498032 Methods for treating immune disorders or cancer with anti-CD40 antibodies |
| 03/03/2009 | US7498031 Treating sensorineural hearing loss or a vestibular disorder by administering an a PM-1antibody or an MR16-1 antibody; Meniere's disease, drug-induced inner ear disorders, viral inner ear disorders, purulent inner ear disorders, temporal bone fracture or acoustic nerve tumor |
| 03/03/2009 | US7498030 Treatment with anti-ErbB2 antibodies and anti-hormonal compounds |
| 03/03/2009 | US7498029 Photoimmunotherapies for cancer using combination therapies |
| 03/03/2009 | US7498027 Methods of treatment using human tumor necrosis factor receptor TR17 antibodies |
| 03/03/2009 | US7498023 Blockade of T cell migration into epithelial GVHD target tissues as an approach to achieving anti-tumor effects against lymphohematopoietic malignancies without GVHD |
| 03/03/2009 | CA2314453C Processes of making north american ginseng fractions, products containing them, and use as immunomodulators |
| 03/03/2009 | CA2238278C Antigenic protein originating in malassezia |
| 02/28/2009 | CA2597151A1 Hiv vaccine |
| 02/26/2009 | WO2009026558A1 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
| 02/26/2009 | WO2009026472A1 Methods for inducing tolerance |
| 02/26/2009 | WO2009026465A2 Composition and methods of making and using influenza proteins |
| 02/26/2009 | WO2009026456A2 Poxvirus methods and compositions |
| 02/26/2009 | WO2009026428A1 Methods and compositions for treatment or prevention of radiation-induced fibrosis |
| 02/26/2009 | WO2009026412A1 Treatment of airway hyperreactivity |
| 02/26/2009 | WO2009026397A2 Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods |
| 02/26/2009 | WO2009026303A1 Human c-fms antigen binding proteins |
| 02/26/2009 | WO2009026274A1 Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| 02/26/2009 | WO2009026177A1 Psma binding ligand-linker conjugates and methods for using |
| 02/26/2009 | WO2009026122A1 Formulations of antibodies and fc-fusion molecules using polycations |
| 02/26/2009 | WO2009025846A2 Activatable binding polypeptides and methods of identification and use thereof |
| 02/26/2009 | WO2009025759A1 Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof |
| 02/26/2009 | WO2009025730A1 Novel cellular factor- containing solution compositions |
| 02/26/2009 | WO2009025669A1 Polymeric linkers containing pyridyl disulfide moieties |
| 02/26/2009 | WO2009025196A1 Foxm1 peptide and medicinal agent comprising the same |
| 02/26/2009 | WO2009025117A1 Cdca1 peptide and pharmaceutical agent comprising the same |
| 02/26/2009 | WO2009025000A1 Mutated salmonella typhi strain and use thereof in a vaccine |
| 02/26/2009 | WO2009024822A2 Diagnostic method and kit |
| 02/26/2009 | WO2009024789A1 Hiv-2 antigenic peptides |
| 02/26/2009 | WO2009024763A2 Combination therapy |
| 02/26/2009 | WO2009024653A1 Anti-idiotypic antibodies which neutralise the inhibitory activity of an inhibitory antibody directed against the c1 domain of factor viii |
| 02/26/2009 | WO2009024534A2 Japanese encephalitis virus (jev) and tick-borne encephalitis virus (tbev) peptides stimulating human t cell responses |
| 02/26/2009 | WO2009024531A1 Method for treating and diagnosing hematologic malignancies |
| 02/26/2009 | WO2009024445A1 Antibodies against human cytomegalovirus (hcmv) |
| 02/26/2009 | WO2009024426A1 Immunizing compositions for inducing 'bystander' killing of pathogens |
| 02/26/2009 | WO2009024239A2 Permissive cells and uses thereof |
| 02/26/2009 | WO2009024208A1 Hypoallergenic molecules |
| 02/26/2009 | WO2009024070A1 Detection and quantitation of urine gelsolin |
| 02/26/2009 | WO2009023955A1 Cytotoxicity mediation of cells evidencing surface expression of cd9 |
| 02/26/2009 | WO2009009591A3 Use of cells to facilitate targeted delivery of nanoparticle therapies |
| 02/26/2009 | WO2009009034A3 Methods and compositions useful in the treatment of mucositis |
| 02/26/2009 | WO2009006638A3 Peptides facilitating retrograde transport and their uses |
| 02/26/2009 | WO2009006301A3 Protein stabilization |
| 02/26/2009 | WO2009004641A3 Adaptation of pitman moore strain of rabies virus to primary chick embryo fibroblast cell cultures |
| 02/26/2009 | WO2009003493A3 Mhc multimers, methods for their generation, labeling and use |
| 02/26/2009 | WO2009002562A3 Complexes of il-15 and il-15ralpha and uses thereof |
| 02/26/2009 | WO2009000929A3 Composition and method for treatment of autoimmune disease |
| 02/26/2009 | WO2009000891A3 Linear expression constructs for production of influenza virus particles |
| 02/26/2009 | WO2008156853A3 Inhibition of filovirus entry into cells and uses thereof |
| 02/26/2009 | WO2008153692A3 Microrna expression profiling of cerebrospinal fluid |
| 02/26/2009 | WO2008151182A3 Herpes simplex virus amplicon vectors derived from primary isolates |
| 02/26/2009 | WO2008150275A3 Methods for preventing and ameiliorating porcine respiratory and reproductive syndrome virus-associated disease by immunizing against porcine ttv infection |
| 02/26/2009 | WO2008136848A3 Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease |
| 02/26/2009 | WO2008136736A3 Immunoregulatory structures from normally occurring proteins |
| 02/26/2009 | WO2008133647A3 Antagonists of pcsk9 |
| 02/26/2009 | WO2008127840A3 Flavivirus ns5a proteins for the treatment of hiv |
| 02/26/2009 | WO2008121992A3 Attenuated viruses useful for vaccines |
| 02/26/2009 | WO2008089144A3 Improved dna vaccination protocols |
| 02/26/2009 | WO2008013948A3 Tyrosine phosphorylation sites |
| 02/26/2009 | WO2007146401A3 Denatured collagen peptides and uses thereof |
| 02/26/2009 | WO2005116260A3 Influenza hemagglutinin and neuraminidase variants |
| 02/26/2009 | US20090055944 Human monoclonal antibodies to be programmed death ligand 1 (pd-l1) |
| 02/26/2009 | US20090054622 Peptide variants of the tumor marker MUC1 and their application |
| 02/26/2009 | US20090054367 Mycobacterial antigens expressed under low oxygen tension |
| 02/26/2009 | US20090054322 Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions |
| 02/26/2009 | US20090053816 Hemoglobin-based methods for prophylaxis, diagnosis and/or treatment of retinal disorders |
| 02/26/2009 | US20090053739 Heme Binding Protein (HBP); use in drug screening agents that modulate FPRL2 (Formyl peptide receptor-like 2 ) |
| 02/26/2009 | US20090053311 Pharmaceutical Compositions for Treating or Preventing Bone Conditions |
| 02/26/2009 | US20090053300 Monoclonal antibody, gene encoding the antibody, hybridoma, pharmaceutical composition, and diagnostic reagent |
| 02/26/2009 | US20090053299 Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery |
| 02/26/2009 | US20090053296 Using cell-mediated immune response to e6 and e7 peptides as diagnostic/prognostic indication of recurrence and/or development of cervical intraepithelial neoplasia (CIN) |
| 02/26/2009 | US20090053294 Anti Mineralocorticoid Therapy of Infection |
| 02/26/2009 | US20090053292 Moraxella catarrhalis protein, nucleic acid sequence and uses thereof |
| 02/26/2009 | US20090053291 Fusion proteins comprising hiv-1 tat and/or nef proteins |
| 02/26/2009 | US20090053290 Transdermal drug delivery compositions and topical compositions for application on the skin |
| 02/26/2009 | US20090053266 Apicomplex vaccine strains of a family of sarcocystidae |
| 02/26/2009 | US20090053265 Antigenic peptides and their use |
| 02/26/2009 | US20090053264 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
| 02/26/2009 | US20090053263 Inhibitors of Enveloped Virus Infectivity |
| 02/26/2009 | US20090053262 Combination vaccine for poultry |
| 02/26/2009 | US20090053261 Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications |
| 02/26/2009 | US20090053259 Vaccines and methods for treatment or prevention of gram negative bacterial infection in a vertebrate subject |
| 02/26/2009 | US20090053258 Assays for diagnosis of tuberculosis and uses thereof |
| 02/26/2009 | US20090053257 Replikin peptides and uses thereof |